145 related articles for article (PubMed ID: 2174343)
1. Receptors for luteinizing hormone-releasing hormone (LHRH) in Dunning R3327 prostate cancers and rat anterior pituitaries after treatment with a sustained delivery system of LHRH antagonist SB-75.
Srkalovic G; Bokser L; Radulovic S; Korkut E; Schally AV
Endocrinology; 1990 Dec; 127(6):3052-60. PubMed ID: 2174343
[TBL] [Abstract][Full Text] [Related]
2. Sustained release formulations of luteinizing hormone-releasing hormone antagonist SB-75 inhibit proliferation and enhance apoptotic cell death of human prostate carcinoma (PC-82) in male nude mice.
Redding TW; Schally AV; Radulovic S; Milovanovic S; Szepeshazi K; Isaacs JT
Cancer Res; 1992 May; 52(9):2538-44. PubMed ID: 1568223
[TBL] [Abstract][Full Text] [Related]
3. Comparison of different agonists and antagonists of luteinizing hormone-releasing hormone for receptor-binding ability to rat pituitary and human breast cancer membranes.
Fekete M; Bajusz S; Groot K; Csernus VJ; Schally AV
Endocrinology; 1989 Feb; 124(2):946-55. PubMed ID: 2536323
[TBL] [Abstract][Full Text] [Related]
4. Receptors for D-Trp6-luteinizing hormone-releasing hormone, somatostatin, and insulin-like growth factor I in MXT mouse mammary carcinoma.
Srkalovic G; Szende B; Redding TW; Groot K; Schally AV
Proc Soc Exp Biol Med; 1989 Dec; 192(3):209-18. PubMed ID: 2574866
[TBL] [Abstract][Full Text] [Related]
5. Regression of nitrosamine-induced pancreatic cancers in hamsters treated with luteinizing hormone-releasing hormone antagonists or agonists.
Szende B; Srkalovic G; Groot K; Lapis K; Schally AV
Cancer Res; 1990 Jun; 50(12):3716-21. PubMed ID: 2160323
[TBL] [Abstract][Full Text] [Related]
6. Effect of microcapsules of luteinizing hormone-releasing hormone antagonist SB-75 and somatostatin analog RC-160 on endocrine status and tumor growth in the Dunning R-3327H rat prostate cancer model.
Yano T; Pinski J; Szepeshazi K; Milovanovic SR; Groot K; Schally AV
Prostate; 1992; 20(4):297-310. PubMed ID: 1351672
[TBL] [Abstract][Full Text] [Related]
7. Receptors for luteinizing hormone-releasing hormone, somatostatin, prolactin, and epidermal growth factor in rat and human prostate cancers and in benign prostate hyperplasia.
Fekete M; Redding TW; Comaru-Schally AM; Pontes JE; Connelly RW; Srkalovic G; Schally AV
Prostate; 1989; 14(3):191-208. PubMed ID: 2471961
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of growth of experimental prostate cancer with sustained delivery systems (microcapsules and microgranules) of the luteinizing hormone-releasing hormone antagonist SB-75.
Korkut E; Bokser L; Comaru-Schally AM; Groot K; Schally AV
Proc Natl Acad Sci U S A; 1991 Feb; 88(3):844-8. PubMed ID: 1992476
[TBL] [Abstract][Full Text] [Related]
9. Recovery of pituitary-gonadal function in male and female rats after prolonged administration of a potent antagonist of luteinizing hormone-releasing hormone (SB-75).
Bokser L; Srkalovic G; Szepeshazi K; Schally AV
Neuroendocrinology; 1991 Aug; 54(2):136-45. PubMed ID: 1662786
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of the pituitary-gonadal axis in nude male mice by continuous administration of LHRH agonists and antagonists.
Redding TW; Schally AV
J Endocrinol; 1990 Aug; 126(2):309-15. PubMed ID: 2144873
[TBL] [Abstract][Full Text] [Related]
11. Detection and partial characterization of receptors for [D-Trp6]-luteinizing hormone-releasing hormone and epidermal growth factor in human endometrial carcinoma.
Srkalovic G; Wittliff JL; Schally AV
Cancer Res; 1990 Mar; 50(6):1841-6. PubMed ID: 2155060
[TBL] [Abstract][Full Text] [Related]
12. Development of radioimmunoassay for a potent luteinizing hormone-releasing hormone antagonist. Evaluation of serum levels after injection of [Ac-3-(2-naphthyl)-D-Ala1, D-Phe(pCl)2, 3-(3-pyridyl)-D-Ala3, D-Cit6, D-Ala10] LHRH.
Csernus VJ; Szende B; Groot K; Redding TW; Schally AV
Arzneimittelforschung; 1990 Feb; 40(2 Pt 1):111-8. PubMed ID: 2110458
[TBL] [Abstract][Full Text] [Related]
13. Direct effects of luteinizing hormone-releasing hormone agonists and antagonists on MCF-7 mammary cancer cells.
Segal-Abramson T; Kitroser H; Levy J; Schally AV; Sharoni Y
Proc Natl Acad Sci U S A; 1992 Mar; 89(6):2336-9. PubMed ID: 1312718
[TBL] [Abstract][Full Text] [Related]
14. Presence of membrane binding sites for [D-TRP6]-luteinizing hormone-releasing hormone in experimental pancreatic cancer.
Fekete M; Zalatnai A; Schally AV
Cancer Lett; 1989 May; 45(2):87-91. PubMed ID: 2567204
[TBL] [Abstract][Full Text] [Related]
15. Luteinizing hormone-releasing hormone (LHRH) agonist restoration of age-associated decline of thymus weight, thymic LHRH receptors, and thymocyte proliferative capacity.
Marchetti B; Guarcello V; Morale MC; Bartoloni G; Raiti F; Palumbo G; Farinella Z; Cordaro S; Scapagnini U
Endocrinology; 1989 Aug; 125(2):1037-45. PubMed ID: 2546733
[TBL] [Abstract][Full Text] [Related]
16. Histological changes in Dunning prostate tumors and testes of rats treated with LH-RH antagonist SB-75.
Szepeshazi K; Korkut E; Szende B; Lapis K; Schally AV
Prostate; 1991; 18(3):255-70. PubMed ID: 2020621
[TBL] [Abstract][Full Text] [Related]
17. New antagonists of LHRH. II. Inhibition and potentiation of LHRH by closely related analogues.
Bajusz S; Csernus VJ; Janaky T; Bokser L; Fekete M; Schally AV
Int J Pept Protein Res; 1988 Dec; 32(6):425-35. PubMed ID: 2469662
[TBL] [Abstract][Full Text] [Related]
18. Blockade of the LH response induced by the agonist D-Trp-6-LHRH in rats by a highly potent LH-RH antagonist SB-75.
Pinski J; Yano T; Miller G; Schally AV
Prostate; 1992; 20(3):213-24. PubMed ID: 1533453
[TBL] [Abstract][Full Text] [Related]
19. Growth inhibition of mouse MXT mammary tumor by the luteinizing hormone-releasing hormone antagonist SB-75.
Szende B; Srkalovic G; Groot K; Lapis K; Schally AV
J Natl Cancer Inst; 1990 Mar; 82(6):513-7. PubMed ID: 2156080
[TBL] [Abstract][Full Text] [Related]
20. Treatment of experimental DMBA induced mammary carcinoma with Cetrorelix (SB-75): a potent antagonist of luteinizing hormone-releasing hormone.
Reissmann T; Hilgard P; Harleman JH; Engel J; Comaru-Schally AM; Schally AV
J Cancer Res Clin Oncol; 1992; 118(1):44-9. PubMed ID: 1530849
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
